Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Airmax: a multi-dose dry powder inhaler.

Gillian M Keating1, Diana Faulds

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 7, 2002
PubMed
Summary

The Airmax inhaler demonstrates improved budesonide delivery and dose consistency compared to Turbuhaler, especially at low airflow rates. Patient preference and ease of use also favor Airmax for asthma management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Biomedical Engineering

Background:

  • Dry powder inhalers (DPIs) are crucial for delivering respiratory medications like budesonide.
  • Device-dependent variability in drug delivery can impact therapeutic efficacy in asthma patients.
  • Optimizing inhaler technology is essential for consistent and effective medication administration.

Purpose of the Study:

  • To evaluate the performance of the Airmax multi-dose dry powder inhaler (MDPI).
  • To compare Airmax with Turbuhaler and a metered-dose inhaler for budesonide delivery in asthma.
  • To assess patient preference and ease of use for the Airmax device.

Main Methods:

  • In vitro studies assessing airflow dependency and dose consistency.
  • In vivo lung deposition studies at low airflow rates.
  • Randomized, double-blind clinical trials comparing Airmax with Turbuhaler for efficacy and patient-reported outcomes.

Main Results:

  • Airmax showed greater dose consistency and less airflow dependency than Turbuhaler in vitro.
  • Lung deposition of budesonide was higher with Airmax at low flow rates.
  • Clinical studies demonstrated equivalent efficacy (FEV(1), symptom improvement) and greater patient preference for Airmax over Turbuhaler.

Conclusions:

  • Airmax offers improved budesonide delivery and dose consistency, particularly in patients with suboptimal inhalation technique.
  • The device provides comparable or superior lung deposition and clinical outcomes to existing inhalers.
  • Airmax is preferred by patients, including children, for its ease of use, suggesting potential for improved adherence.

Related Experiment Videos